We developed a PCR-based method to monitor clonogenic IgH VDJ rearrangement as a possible predictor of relapse in patients with acute B-ALL after allogeneic bone marrow transplantation (BMT). We studied 23 patients at diagnosis, before and after BMT. At the time of BMT, 13 patients were in first complete remission, eight in second complete remission and two in relapse. Four patients were PCR negative before BMT and remained PCR negative also after BMT (؊/؊ pattern). They are still in remission after a median follow-up of 41 months. Nineteen patients were MRD-positive before BMT: three were PCR negative at first determination after BMT (+/؊ pattern) and maintain remission. Sixteen patients were PCR-positive at first determination after BMT (+/+ pattern): five became PCR negative (+/+/؊ pattern) (four with chronic graft-versus-host disease (GVHD) and two after donor lymphocyte infusions (DLI)). Nine patients remained PCR-positive (+/+/+ pattern) (four remain in remission, and six relapsed); two patients died before transplant. In conclusion, PCR negative patients before BMT remained negative post-BMT; many pre-BMT positive patients had initial MRD positivity after BMT: 37% of them achieved a molecular remission with cGVHD or DLI. significant relapse risk. 4 A lower relapse rate in ALL patients with chronic graft-versus-host disease (cGVHD) has been reported and GVHD was the most significant predictor of relapse in multivariate analysis in a large series of patients.
significant relapse risk. 4 A lower relapse rate in ALL patients with chronic graft-versus-host disease (cGVHD) has been reported and GVHD was the most significant predictor of relapse in multivariate analysis in a large series of patients. 3 This study suggests that the alloimmune response is crucial both to prevent leukemic relapse and to improve survival. Nevertheless donor lymphocyte infusion (DLI) does not exert a significant antileukemic effect in ALL patients relapsing after BMT, 5 differently from patients with CML, where more than 80% of patients relapsing after BMT are responsive to DLI. A possible explanation for this different behavior relies on the fact that in CML patients DLI is performed in early (ie cytogenetic) relapse, possibly when the tumor burden is low. According to this hypothesis, in CML DLI are ineffective in hematologic relapse, especially when it occurs in the accelerated or blastic phase. In CML this has suggested close cytogenetic and molecular monitoring after BMT. 5 Improvement of the outcome in ALL patients seems therefore strictly associated with the possibility to intensify the alloimmune effect in order to prevent relapse or to treat it in the earliest phase. Qualitative and possibly quantitative molecular follow-up of minimal residual disease (MRD) is actually the most sensitive tool to disclose residual clonal cells, to detect early relapse and to direct immune intervention. 5 In ALL patients, minimal residual disease may be studied by monitoring clonogenic IgH VDJ or T cell receptor (TCR) gene rearrangement.
We have developed a three-step single-strand conformational polymorphism polymerase chain reaction (SSCP-PCR) 6-8 strategy, which is able to detect clonal B lymphoid cells at a frequency of one among 10 5 -10 6 cells. SSCP is based on the fact that variations in the sequence as small as one base change alter the secondary structure of singlestranded DNA, eg induce modifications of electrophoretic mobility, which are observed as band shifts. Differential transient interactions of the bent and curved molecules with the gel during electrophoresis cause a different migration of the various sequence isomers. Since this method proved to be simple, rapid and reliable, it might be considered as an alternative to clono-specific primer-based PCR, 9,10 and might be particularly useful in monitoring patients with B cell lymphoproliferative disorders in complete hematological remission (CR).
The aim of the present study was to test whether molecular monitoring of MRD would correlate with clinical events, in patients with B-ALL undergoing allogeneic BMT.
Matherials and methods

DNA sources
DNA was extracted from bone marrow at the time of initial evaluation, at the end of conventional therapy and after transplantation. When fresh bone marrow samples were not available, DNA was extracted either from unpreserved, unstained cover slips prepared during bone marrow aspirates, or from 10 micron slices of preserved paraffin-embedded bone biopsy. 11 Genomic DNA was prepared as previously described. 12 The integrity of extracted DNA was tested by PCR amplification of X-linked HUMARA gene. 13 
PCR conditions
Clonal DNA amplification of the diagnosis sample was tested in different reactions containing each of the seven Vh specific primers.
14 Primer sequences and cycling parameters were published previously. [6] [7] [8] All reactions were amplfied on Omnigene Hybaid thermal cycler using the hot start method. Oligonucleotides were synthesized and purchased from TIB MOLBIOL CBA, Genova, Italy. Special precautions as recommended by Kwok and Higuchi 15 were taken to prevent cross-contamination. Furthermore, a control sample containing all reagents except the DNA template was included in each amplification battery to detect contamination in any of the reagents or cross-contamination among tubes. Samples were amplified at least twice to ensure consistency and to prevent sporadic false-positive results.
PCR products were analyzed by gel electrophoresis in 2% high resolution agarose stained with ethidium bromide.
Clonal Jh rearrangement resulted in a distinct band within the expected size range of~300 bp. This clonal band corresponds to the PCR product that we should sequence in order to construct clono-specific primers or probes. These bands have their own electrophoretic mobility and they represent the desease-specific marker. Vh-specific primers which are able to amplify the clonal band were used for all follow-up samples from the same patient.
MRD analysis
MRD analysis was performed for each patient at the end of conventional chemotherapy and after transplantation. In our series, only bone marrow samples were analyzed.
Therefore, we applied our three step SSCP-PCR as previously described. [6] [7] [8] This method allows the detection of one malignant cell among 10 5 normal cells. Each follow-up sample amplification was always electrophoresed in the presence of the corresponding diagnosis clonal product. After SSCP migration each monoclonal band usually resolves in two dinstinct bands, due to the denaturation of the two strands. Amplification of the Jh gene from a polyclonal lymphoid population does not show a preferential PCR product.
When relapse occurred, one of the clonal populations present at diagnosis was always detected. In our study we did not observe any subclonal evolution which would indicate a clonal variation.
Cytogenetic analysis
Cytogenetic analysis was performed using the Q-banding technique on bone marrow cells routinely processed after 24 h of culture. For all patients the karyotype was analyzed at diagnosis and after the induction therapy (at the end of the induction therapy); at least 15 metaphases were examined. 16 
Chimerism analysis
DNA from recipient and donor bone marrow was extracted by common phenol-chloroform protocols. From 1 to 5 ng of extracted DNAs were amplified in a total volume of 50 l and mineral oil was used to seal the reaction. In order to avoid allelic drop-out and reduce primer-dimer formation, each sample was combined with a commercial internal lane size standard GS 2500, loaded into a 4% polyacrylamide gel and electrophoresed for 2.5 h on an Applied Biosystems DNA 377 (Applied Biosystems, Foster City, CA, USA). Sequencer analysis was conducted using Genescan 672 Software (ABD).
The use of the inner standard marker allows an exact definition of the molecular size for each lane, so that electrophoretic mobility does not interfere with the results. Alleles for each marker are clearly identifiable by a size range window which allows each one of them to be assigned to a precise class of repeat numbers.
In this regard, three multiplex reactions were developed in order to assess the identification of 13 DNA markers. 17, 18 Following loci were explored and assembled. (A) HumF 13A01, HumTH01, HumvWA31|a, HumFES\FPS and D19S253; (B) HumF13B, HumTPOX, HumCSF1 PO, HumLPL and HumvWA31\A; (C) HumFGA, D8S1179, HumTH01, HumvWA31\A, D18S51 and D21S11.
Inner controls are provided by HumvWA31\A and Hum-THO1 markers, the former amplified in all the reactions and the latter in A and C multiplexes. Sex chromosomes were investigated by amplification of the X-Y homologous gene amelogenin. 19 This method, according to current literature, 17, 18 has been called short tandem repeats (STR).
Patients' characteristics
We have studied 23 B-lineage ALL patients, transplanted between 1990 and 1999. Patients were eligible for the study if samples collected at diagnosis, before and at least once after BMT were available. Patients' features are summar-ized in Table 1 . Median age at BMT was 29 years (range 13-38) and median duration of follow-up was 719 days (range 150-2400). At the time of BMT, 13 patients were in first complete remission (CR1), eight in second complete remission (CR2) and two in relapse. Fourteen patients had a normal karyotype at diagnosis (one was bcr-abl positive); cytogenetic abnormalities were detected in nine patients: t(9;22) in 3, +8 in one, Ϫ7 in one and t(4;11) in two, complex karyotype in two.
In 15 patients MRD was studied on samples collected within 3 months after BMT. For all patients samples were available during the follow-up, after 3 months after BMT. After BMT cytogenetic analysis was performed in all patients, whereas chimerism was assessed by short tandemrepeats (STRs) in 14 patients.
Eighteen patients received BMT from their HLA-identical siblings, two from matched unrelated donors, one from his HLA-identical father, and one from his one-antigenmismatched sibling. One patient received syngeneic marrow from her twin.
In 19 patients the conditioning regimen was cyclophosphamide (CY) (60 mg/kg once daily on days 1 and 2 ) and fractionated total body irradiation (TBI) (9.9-12 Gy in 3-6 fractions). Three patients received a different combination of thiotepa (TT) (10-15 mg/kg) and cyclophosphamide (respectively, 100-120-150 mg/kg). A 53-year-old patient received a less intensive conditioning regimen with fludarabine 90 mg/m 2 and cyclophosphamide 900 mg/m 2 followed by reinfusion of peripheral blood stem cells (PBSC).
All the remaining patients received unmanipulated bone marrow. Cyclosporin A (1 mg/kg/day) and methotrexate (10 mg on day 1, and 8 mg on days 3, 6 and 11) were administered as GVHD prophylaxis. Five high risk patients received donor lymphocyte infusions (DLI) (two after the first detection of MRD positivity).
Acute graft-versus-host disease was scored according to Bone Marrow Transplantation standard morphological, clinical and biochemical criteria based on the involvement of skin (% of involved skin area), liver (serum levels of bilirubin) or intestine (volume of diarrhoea and/or ileus). Acute GVHD was clinically graded as 0-IV. Chronic GVHD was also diagnosed according to morphological criteria and was graded as absent, limited or extensive.
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Results
Monoclonal VDJ rearrangements were detected in all patients. Whereas five patients displayed only one monoclonal rearrangement, two different clones were detected in eight cases, and three in the remaining 10. In all patients, MRD monitoring was performed separately for each clone in the various phases of therapy.
The clinical and molecular follow-up of patients is reported in Tables Figure 5 ). Patients remained disease-free for a median of 5 months (range 2-12). Acute GVHD score was р1 in five of them. All died of disease progression (two after reinduction therapy and second BMT) (Figure 4 ). Of the remaining five patients, two died in clinical remission due to transplantation-related causes (pneumonia and extensive cGVHD) and three are alive and disease-free after 65 and 96 months from BMT (UPN 602, 826 and 1134) with grade II-III cGVHD ( Figure 6 ).
Discussion
Twenty-three ALL patients, whose DNA samples collected before and after BMT were available, were evaluated for clonogenic IgH VDJ rearrangement, through a three-step SSCP-PCR method. As far as we know this is the first study aimed at evaluating a possible correlation between molecular MRD follow-up and clinical outcome in adult ALL patients undergoing BMT. In our series of patients pre-BMT PCR negativity (four cases) was always associated with absence of MRD and favorable post BMT outcome. Other reports have emphasized the negative prognostic significance of MRD positivity at the end of chemotherapy in series of childhood 20 and adult 21 ALL patients. Further- Pos (11) Neg (3) Neg (5) Pos (9) Disease free (3)
Disease free (4) Disease free (5) Relapsed ( more, in the ongoing German ALL trial, standard risk patients will proceed to stem cell transplant only if MRD was detected by molecular analysis at the end of consolidation therapy.
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The most interesting behavior is represented by the group of pre-BMT PCR-positive patients. Three of them became PCR-negative at the first evaluation after BMT and absence of MRD persisted, suggesting that the conditioning regimen might have eradicated the disease.
Among the remaining 16 patients, two died of transplantrelated causes. In the remaining 14 patients, PCR positivity persisted after BMT for a long period but this was followed by relapse in only six patients whose acute GVHD score Bone Marrow Transplantation was Ͻ1. Clinical remission was maintained in the other eight patients, in whom immune surveillance and/or a graftversus-leukemia effect was sustained either by chronic GVHD or DLI. Five of them eventually became PCR-negative, indicating that alloimmune mechanisms had reduced residual clonal cells below the level of MRD detection. Interestingly in two of them, MRD became undetectable after DLI, suggesting that this immunotherapy might play an effective role even in ALL, if treatment is adopted early, when a low number of neoplastic cells is present.
Finally we observed that even full STR chimerism can be associated with MRD detection and even relapse. This observation confirms that probably these two molecular techniques give different information regarding the longterm outcome of transplanted patients.
The role of immune surveillance and GVL effect has been further confirmed by our report, as already suggested by clinical and molecular studies. 2, 3, 23 Although this report is a descriptive and retrospective study including a relatively small number of patients, it clearly showed that serial PCR-based MRD evaluations may select patients at higher risk of relapse for whom immunotherapy with DLI may be of benefit. Furthermore, by comparing PCR status pre-and post-donor lymphocyte infusion, the molecular study may check the efficacy of DLI in a single patient. The new technique of real-time PCR 24 might further improve the value of molecular monitoring of MRD in predicting relapse and might help to tailor (or to modulate) the dose and the timing of DLI according to individual risk.
